ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1167

Towards an Autologous 3D Skin-like Tissue Harboring Patient-Derived Fibroblasts, Keratinocytes, T-cells and Macrophages
Abstract Number: 2064

Trajectories of Disease Activity in a Longitudinal Registry of Pediatric SLE
Abstract Number: 1172

Transcription Analysis of Macrophages Reveals Important Changes Induced by Systemic Sclerosis Fibroblasts
Abstract Number: 0586

Transcription Factor Fli-1 Impacts CXCL13 Expression and Renal Inflammation in Lupus-like Nephritis of Adult MRL/lpr Mouse
Abstract Number: 2223

Transcriptome Profiling and Autoimmunity-related Serological Markers Identify Tumour Protein P53 and Complement C3a Receptor 1 as Drug Targets in Neuropsychiatric Systemic Lupus Erythematosus
Abstract Number: 1120

Transcriptome-Wide Association Study of Sjögren’s Disease Risk Alleles Identifies Novel Genes with Altered Expression in Minor Salivary Gland and Other Tissues
Abstract Number: 0647

Transcriptomic Analysis of Lupus Nephritis Kidneys Identifies Molecular Endotypes
Abstract Number: 1147

Transcriptomic Changes Induced by Tocilizumab in Ex-Vivo PBMCs from Patients with GCA in Remission. Predictors of Response
Abstract Number: 2260

Transcutaneous Vagal Nerve Stimulation Improves Destabilized Medial Meniscus-Induced Osteoarthritis Pain Associated with Significant Serum Biomarker Changes
Abstract Number: 2180

Transfer of Monoclonal ACPAs Induces Pain, Bone Loss and Tenosynovitis in Mice in a Peptidyl Arginine Deiminase-4 Dependent Manner
Abstract Number: 1934

Transition Readiness Before versus After Adolescents with Rheumatic Disease Transition to Adult Care
Abstract Number: 0808

Transitional Care in Juvenile Idiopathic Arthritis: Timing, Prevalence of Subtypes and Treatment Profile in a Spanish Tertiary Hospital
Abstract Number: 0338

Transitioning from Cutaneous to Systemic Lupus Erythematosus: An Analysis of Incidence and Risk Factors
Abstract Number: 1294

Translation and Cross-cultural Adaptation of the CORS into Spanish
Abstract Number: 0417

Treating Spondyloarthritis Early: Does It Matter? Results from a Systematic Literature Review

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].